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Table 1.
BMT
Group
Path-
ology
Index
BALF Analysis
Total
Cells
( 106)
macs
( 106)
CD8
T Cells
( 103)
GR1
Cells
( 103)
Protein
(g/ml)
TNF
(pg/ml)
Syngeneic 0.7  0.3 0.72  0.15 0.69  0.14 7.2  1.5 7.2  1.5 247  38 0  0
Allo
CCR1/ 5.2  0.8 2.6  0.6 1.9  0.5 473.2  69.3 87.3  14.3 517  58 24.6  1.4
Allo
CCR1/ 2.7  0.6* 1.1  0.1* 0.82  0.1 68.8  7.0** 15.3  1.6** 320  51* 1.0  0.6*
*p 
 0.05; **p 
 0.01; p  0.06.
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MYELOABLATIVE MATCHED UNRELATED DONOR STEM CELL TRANS-
PLANT BY INFUSION OF BACKUP AUTOLOGOUS PERIPHERAL BLOOD
STEM CELLS
Khan, S.A.; Moreb, J.S. University of Florida College of Medicine,
Gainesville, FL.
Acute graft vs. host disease (GVHD) is major concern in stem cell
transplantation and is associated with signiﬁcant morbidity and mor-
tality. The incidence of grade II-IV acute GVHD is 78% and grade
III-IV is 36% afterHLAmatched unrelated donor (MUD) transplant.
We report a successful use of infusion of autologous peripheral blood
stem cells to treat severe, refractory grade 4 GVHD after a non-
myeloablative MUD transplant. Patient was a 55 years old white
female with non-secretory MM presenting with pathological fracture
of her arm. She was initially treated with VAD and then hyper-CVAD
chemotherapy and achieved partial remission (PR). Subsequently, she
underwent autologous peripheral blood stem cell transplant (PB-
SCT). She progressed 2 months after autologous PBSCT and became
refractory to Thalidomide as well as chemotherapy combination of
CCNU, VP-16, Cytoxan and prednisone. Therefore, she underwent
a non-myeloablative MUD PBSCT after conditioning with Fludara-
bine, ATG and Busulfan. Post transplant evaluation revealed persis-
tent disease with 60% plasma cells and mixed chimerism with 91%
male donor cells, so immunosuppressive therapy was tapered. Two
weeks later she developed severe grade 3 GVHD involving skin and
gut which progressed to grade 4GVHD and was refractory to therapy
with FK506, Steroids, Cellcept, Daclizumab, Remicade and Thalid-
omide. She developed severe malabsorption with albumin as low as
1.6. We gave her cyclophosphamide followed by backup autologous
stem cells in order to stop the GVHD by creating “host-versus-graft
effect”. On day90 she received 10 106/kg CD34 cells and 1.4
107/KG CD3 cells. Four weeks later she still had 99% donor chi-
merism with no signiﬁcant change in her GVHD symptoms and
therefore she was given 2nd infusion of 42 106/kg CD34 cells and
5.7  107/kg CD3 cells. Subsequently, she recovered slowly from
her GVHD and was discharged after 3 months of hospitalization.
Currently she is 2.5 years post transplant without any immunosup-
pressive therapy and most recent BM test showed 100% donor chi-
merism and stable MM with 10% plasma cells. This case demon-
strates feasibility of infusion of autologous stem cells to control
refractory GVHD. A similar case was previously reported (Ricordi et
al, Cell Transplantation 1994;3:187). The mechanism for such effect
is not clear but may involve development of tolerance of donor T
lymphocytes vs. host without inhibiting GVL effect or causing mixed
chimerism.
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CARDIAC MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE
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Schultz, K.R.6 1. University of North Carolina School of Medicine,
Chapel Hill, NC; 2. Children’s Memorial Hospital, Chicago, IL; 3.
University of Iowa, Iowa City, IA; 4. Children’s Mercy Hospital, Kansas
City, MO; 5. M.D. Anderson Cancer Center, Houston, TX; 6. British
Columbia Children’s Hospital, Vancouver, BC, Canada.
Graft-versus-host disease (GVHD) is a major cause of morbidity
and mortality after bone marrow transplantation. Well-docu-
mented manifestations of GVHD include dermatologic, gastroin-
testinal, hepatic, pulmonary, musculoskeletal, and hematologic
manifestations and sicca syndrome. To date, the heart has only
rarely been reported to be a target of GVHD. We report 11
patients who developed bradycardia, coronary artery disease, or
cardiomyolysis in association with acute or chronic GVHD. Eight
patients were male and 3 were female. Patients were 4 months-19
years old (median 12 yrs). Three patients received post-transplant
immunotherapy. The patient with Fanconi anemia/AML received
IL-2 for recurrent leukemia and two recipients of T cell-depleted
grafts received DLI, one for relapse and one for graft rejection.
Regarding possible risk factors, six patients had received total body
irradiation and ﬁve patients had received anthracyclines prior to
transplant. Other possible causes for heart block and bradycardia
including electrolyte abnormalities and medications were excluded.
Of eight patients with bradycardia, seven had resolution of brady-
cardia (including heart block and sinus node failure) and one had
improvement with increased immunosuppression. Three patients
had a recurrence of bradycardia and GVHD following weaning of
immunosuppression. The severity of these manifestations ranged
from asymptomatic to fatal. The incidence of cardiac manifesta-
tions was estimated at 9.3%. TBI and prior anthracycline therapy
did not seem to be signiﬁcant risk factors because approximately
half of patients had not received either. The majority of patients
had alternative donors and 3 had post-transplant immunotherapy.
Although uncommon, it is important to recognize these cardiac
manifestations as they may reﬂect GVHD activity and may be
reversible by increasing immunosuppression.
Cardiac Manifestations of GVHD
Age Disease
Stem Cell
Source GVHD
Cardiac
Manifest-
ation
HR during
Bradycardia
Normal
HR for
Age
Cardiac
Outcome
4 mo SCID Haplo
father
BM
Hyper-
acute
&
chronic
Complete
heart
block
30–40’s 90–140’s Resolved
w/
MP/
CSA
2 yr Fanconi,
AML
MSD BM Atypical,
after
IL-2
for
GVL
Sinus node
failure
30–40’s 90–140’s Resolved
w/
MP/
Tac
18 mo Wiskott-
Aldrich
5/6 MUD
cord
Acute &
chronic
Bradycardia 50–90’s 90–140’s Resolved
w/
MP/
HCQ
21 mo CID 4/6 MUD
cord
Acute &
chronic
Bradycardia 50–80’s 90–140’s Improved
w/
MP/
Pento-
ostatin
13 yr Refractory
LCL
MSD
PBSC
Acute &
chronic
Bradycardia 50’s 60–110 Resolved
w/
MP
17 yr ALL, CR4 6/6 MUD
PBSC
Acute Bradycardia 50’s 60–110 Resolved
w/
MP/
Zena-
pax
12 yr ALL, CR3 Haplo
mother
PBSC
Acute &
chronic
Bradycardia 50–60’s,
low 40
60–110 Resolved
w/
MP
13 yr MDS,
AML
Haplo
mother
PBSC
Acute &
chronic
Bradycardia 50–60’s 60–110 Resolved
w/
MP
18 yr ALL, CR3 MSD
PBSC
Acute &
chronic
Cardiomy-
olysis
— — Sudden
death
19 yr AML,
relapse
MSD BM Acute &
chronic
Coronary
arterioscler-
osis
— — Sudden
death
25 mo Wiskott-
Aldrich
6/6 MUD
BM
Acute &
chronic
Coronary
arterioscler-
osis
— — Sudden
death
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RELATIONSHIP BETWEEN RACE AND RISK OF ACUTE GRAFT-VERSUS-
HOST DISEASE
Klumpp, T.R.; Jillella, A.P.; Ulicny, J.A.; Emmons, R.V.B.; Mangan,
K.F. Fox Chase-Temple BMT Program, Philadelphia, PA.
Several groups have reported an increased incidence of acute
GVHD among African-American transplant recipients. However,
informal communications with other BMT teams suggest that
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